Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

For the current quarter ending in September, Abbott expects its per-share earnings to range from $1.28 to $1.32. The company ...

Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%.

Shares of Abbott Laboratories (NYSE:ABT) lost ~5% in the premarket on Thursday after the MedTech company provided its ...

If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock ...

Abbott Laboratories reported second-quarter earnings that slightly exceeded analyst expectations, but shares fell 2.5% following the results.

Abbott Laboratories’ second quarter results echoed Johnson & Johnson’s, with med tech performing the hero’s work with strong growth. Overall, Abbott slightly beat expectations with sales up 6.9% ...

For traders who focus on events, examining the historical reactions of the stock to earnings announcements can offer useful ...

Q2 2025 Results Conference Call July 17, 2025 9:00 AM ETCompany ParticipantsMichael Comilla - Vice President of ...